Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Arizona State Retirement System

Arizona State Retirement System lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 19,129 shares of the medical equipment provider’s stock after selling 327 shares during the quarter. Arizona State Retirement System’s holdings in Lantheus were worth $1,186,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Trueblood Wealth Management LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $712,000. Silverberg Bernstein Capital Management LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $1,385,000. Reinhart Partners LLC. increased its stake in shares of Lantheus by 50.4% in the 4th quarter. Reinhart Partners LLC. now owns 1,356,273 shares of the medical equipment provider’s stock valued at $84,089,000 after purchasing an additional 454,753 shares in the last quarter. Ulland Investment Advisors LLC purchased a new position in shares of Lantheus in the 4th quarter valued at about $135,000. Finally, Pacer Advisors Inc. increased its stake in shares of Lantheus by 137.6% in the 4th quarter. Pacer Advisors Inc. now owns 13,664 shares of the medical equipment provider’s stock valued at $847,000 after purchasing an additional 7,913 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH stock opened at $60.25 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. The business has a 50 day simple moving average of $60.25 and a 200-day simple moving average of $63.06. The firm has a market capitalization of $4.13 billion, a PE ratio of 12.98 and a beta of 0.54. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. 2.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the company. B. Riley cut their price objective on Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, January 10th. TheStreet lowered Lantheus from a “b-” rating to a “c” rating in a research note on Monday, December 18th. JMP Securities reiterated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reiterated a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. Finally, StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.14.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.